Sanofi says Cemiplimab skin cancer treatment gets FDA “Breakthrough Designation”

PARIS, Sept 8 (Reuters) – Sanofi and RegeneronPharmaceuticals said on Friday that the U.S. Food andDrug Administration (FDA) has granted “Breakthrough Therapy”designation status to their skin cancer treatment Cemiplimab.
The post Sanofi says Cemiplimab skin cancer treatment gets FDA “Breakthrough Designation” appeared first on RocketNews | Top News Stories From Around the Globe.